OPKO Health

OPK · NASDAQ

$1.66+$0.05 (+3.11%)TodayMarket closed · Oct 20, 7:47 PM ET

Prev close $1.61

OPK analyst rating

BuyConsensus of 4 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy2
Hold2
Underperform0
Sell0

12-month price target · 4 analysts

Average $4.93 (+197.0% upside)

Low: $3.03
Now: $1.66
High: $8.93

Upgrades and downgrades

The latest rating actions, newest first

OPK analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Oct 16, 2026	Maintains	Overweight	$3.00 → $4.00	40%
Barrington Research	Oct 16, 2026	Upgrade	Market Perform → Outperform	—	44%
Barrington Research	Apr 29, 2026	Downgrade	Outperform → Market Perform	—	44%
Barrington Research	Mar 2, 2026	Maintains	Outperform	$2.25 → $1.50	44%
JP Morgan	Nov 20, 2025	Initiates	Neutral	—	40%
Jefferies	Oct 31, 2025	Downgrade	Buy → Hold	$2.00 → $1.60	29%
Barrington Research	Oct 30, 2025	Maintains	Outperform	$2.25	44%

The case for and against

Updated Oct 18, 2026

Bull case

OPKO Health is viewed positively because the sale of the remaining BioReference laboratory testing business to LabCorp for $722 million upfront, plus up to $150 million tied to 4Kscore revenues, materially strengthens the balance sheet and simplifies the story. The company ended 2Q:26 with $314.4 million in cash against $349 million in debt, while its pharmaceutical assets and distributor business retain meaningful value through 2027E revenues, NGENLA profit share, and Rayaldee. Its ModeX pipeline adds multiple near- to mid-term catalysts, including Phase I/IIa and Phase I programs such as MDX2001, MDX2003, MDX2004, MDX2301, and MDX3001, which together support an expanding valuation base.

Bear case

OPKO Health is facing a weak fundamental setup after first-quarter revenue of $124.2 million and EPS of -$0.07 both missed expectations, with Diagnostics at $72.2 million, Rayaldee at $6.3 million, and other revenue at $14.0 million all coming in below estimates. The company’s cash, equivalents, and restricted cash of about $341.9 million versus total debt of roughly $345.7 million leaves limited financial flexibility, especially given stated risks that NGENLA, Rayaldee, and BioReference may miss forecasts and that ModeX’s vaccines and antibodies may fail in the clinic. Although management affirmed FY/26 revenue guidance of $530 million to $560 million, the need for a sharp 2H/26 acceleration and the reduced credibility of the upper end make the outlook for execution and earnings quality unattractive.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.